Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EHVA P01: Prophylactic HIV Vaccine Trial of DREP Alone and in Combination With CN54gp140/MPLA-L
NCT04844775Phase 1Completed
- Sponsor
- ANRS
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of DREP-HIV-PT1 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by ANRS. Primary endpoints: Any adverse reaction that results in a clinical decision to stop immunisations (Part 1) at 4 weeks, Any adverse reaction that results in a clinical decision to stop immunisations (Part 2) at 9 weeks and 1 more. Started Aug 2022; status: completed.
02
Drugs
DREP-HIV-PT1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04844775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844775.